Verition Fund Management LLC Buys Shares of 8,540 Mednax, Inc (MD)

Verition Fund Management LLC bought a new stake in Mednax, Inc (NYSE:MD) during the second quarter, according to its most recent filing with the SEC. The firm bought 8,540 shares of the company’s stock, valued at approximately $516,000.

A number of other large investors have also recently bought and sold shares of MD. Grandeur Peak Global Advisors LLC boosted its holdings in Mednax by 6.5% in the 2nd quarter. Grandeur Peak Global Advisors LLC now owns 200,125 shares of the company’s stock valued at $12,082,000 after purchasing an additional 12,300 shares during the period. Sterling Capital Management LLC boosted its holdings in Mednax by 2.4% in the 2nd quarter. Sterling Capital Management LLC now owns 1,048,652 shares of the company’s stock valued at $63,307,000 after purchasing an additional 24,228 shares during the period. BB&T Investment Services Inc. bought a new stake in Mednax in the 2nd quarter valued at $243,000. Nomura Holdings Inc. bought a new stake in Mednax in the 2nd quarter valued at $347,000. Finally, Earnest Partners LLC boosted its holdings in Mednax by 0.4% in the 2nd quarter. Earnest Partners LLC now owns 1,483,337 shares of the company’s stock valued at $89,549,000 after purchasing an additional 5,595 shares during the period.

In related news, insider John C. Pepia sold 3,000 shares of the company’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $42.85, for a total value of $128,550.00. Following the transaction, the insider now directly owns 35,569 shares in the company, valued at $1,524,131.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 2.40% of the company’s stock.

Mednax, Inc (NYSE MD) opened at 42.12 on Thursday. The stock’s 50 day moving average is $42.95 and its 200-day moving average is $52.44. Mednax, Inc has a 12-month low of $40.78 and a 12-month high of $72.13. The company has a market capitalization of $3.88 billion, a P/E ratio of 13.41 and a beta of 0.37.

Mednax (NYSE:MD) last released its quarterly earnings results on Friday, July 28th. The company reported $0.85 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.81 by $0.04. Mednax had a net margin of 8.78% and a return on equity of 11.89%. The business had revenue of $843.00 million for the quarter, compared to the consensus estimate of $849.49 million. During the same period in the prior year, the company posted $1.03 earnings per share. Mednax’s revenue was up 9.2% compared to the same quarter last year. On average, equities analysts predict that Mednax, Inc will post $3.30 earnings per share for the current fiscal year.

MD has been the subject of a number of research reports. Stephens raised shares of Mednax from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $55.00 to $68.00 in a report on Thursday, June 22nd. BidaskClub raised shares of Mednax from a “sell” rating to a “hold” rating in a report on Friday, June 23rd. Jefferies Group LLC reissued a “hold” rating and issued a $53.00 price target (up from $50.00) on shares of Mednax in a report on Thursday, July 6th. Mizuho reissued a “neutral” rating and issued a $48.00 price target (down from $62.00) on shares of Mednax in a report on Tuesday, August 1st. Finally, Robert W. Baird reissued a “hold” rating and issued a $47.00 price target on shares of Mednax in a report on Sunday, September 3rd. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and two have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $55.44.

TRADEMARK VIOLATION WARNING: This report was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://ledgergazette.com/2017/10/19/verition-fund-management-llc-buys-shares-of-8540-medna

A number of other large investors have also recently bought and sold shares of MD. Grandeur Peak Global Advisors LLC boosted its holdings in Mednax by 6.5% in the 2nd quarter. Grandeur Peak Global Advisors LLC now owns 200,125 shares of the company’s stock valued at $12,082,000 after purchasing an additional 12,300 shares during the period. Sterling Capital Management LLC boosted its holdings in Mednax by 2.4% in the 2nd quarter. Sterling Capital Management LLC now owns 1,048,652 shares of the company’s stock valued at $63,307,000 after purchasing an additional 24,228 shares during the period. BB&T Investment Services Inc. bought a new stake in Mednax in the 2nd quarter valued at $243,000. Nomura Holdings Inc. bought a new stake in Mednax in the 2nd quarter valued at $347,000. Finally, Earnest Partners LLC boosted its holdings in Mednax by 0.4% in the 2nd quarter. Earnest Partners LLC now owns 1,483,337 shares of the company’s stock valued at $89,549,000 after purchasing an additional 5,595 shares during the period.

In related news, insider John C. Pepia sold 3,000 shares of the company’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $42.85, for a total value of $128,550.00. Following the transaction, the insider now directly owns 35,569 shares in the company, valued at $1,524,131.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 2.40% of the company’s stock.

Mednax, Inc (NYSE MD) opened at 42.12 on Thursday. The stock’s 50 day moving average is $42.95 and its 200-day moving average is $52.44. Mednax, Inc has a 12-month low of $40.78 and a 12-month high of $72.13. The company has a market capitalization of $3.88 billion, a P/E ratio of 13.41 and a beta of 0.37.

Mednax (NYSE:MD) last released its quarterly earnings results on Friday, July 28th. The company reported $0.85 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.81 by $0.04. Mednax had a net margin of 8.78% and a return on equity of 11.89%. The business had revenue of $843.00 million for the quarter, compared to the consensus estimate of $849.49 million. During the same period in the prior year, the company posted $1.03 earnings per share. Mednax’s revenue was up 9.2% compared to the same quarter last year. On average, equities analysts predict that Mednax, Inc will post $3.30 earnings per share for the current fiscal year.

MD has been the subject of a number of research reports. Stephens raised shares of Mednax from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $55.00 to $68.00 in a report on Thursday, June 22nd. BidaskClub raised shares of Mednax from a “sell” rating to a “hold” rating in a report on Friday, June 23rd. Jefferies Group LLC reissued a “hold” rating and issued a $53.00 price target (up from $50.00) on shares of Mednax in a report on Thursday, July 6th. Mizuho reissued a “neutral” rating and issued a $48.00 price target (down from $62.00) on shares of Mednax in a report on Tuesday, August 1st. Finally, Robert W. Baird reissued a “hold” rating and issued a $47.00 price target on shares of Mednax in a report on Sunday, September 3rd. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and two have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $55.44.

TRADEMARK VIOLATION WARNING: This report was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://ledgergazette.com/2017/10/19/verition-fund-management-llc-buys-shares-of-8540-mednax-inc-md.html.

Mednax Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Institutional Ownership by Quarter for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply